Primary sclerosing cholangitis (PSC) is a condition causing long-term inflammation and scarring (fibrosis) of bile ducts in the liver. These ducts are tubes that allow the liquid (bile) produced by the liver to pass through the intestine allowing fat digestion. This disease predominantly affects men between the age of 25 and 40 years. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.
The report offers detailed coverage of Primary Sclerosing Cholangitis industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Primary Sclerosing Cholangitis by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
The report forecast global Primary Sclerosing Cholangitis market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2028.
First, this report covers the present status and the future prospects of the global Primary Sclerosing Cholangitis market for 2015-2028.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Shire Plc.
NGM Biopharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Conatus Pharmaceuticals, Inc.
Durect Corporation
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.
At the same time, we classify Primary Sclerosing Cholangitis according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Market by Order Type
Type I
Type II
Market by Application
Hospital
Clinics
Other
Market Segment as follows:
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Primary Sclerosing Cholangitis market for the forecast period 2020 - 2028?
• What are the driving forces in the Primary Sclerosing Cholangitis market for the forecast period 2020 - 2028?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Primary Sclerosing Cholangitis industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?